1. 1. British Pharmacopœia, Her Majesty Stationery Officer, London, UK, 2013.
2. 2. Cazaubon C, Gougat J, Bousquet F, Guiraudou P, Gayraud R, Lacour C, Roccon A, Galindo G, Barthelemy G, Gautret B, Bernhart C, Perreaut P, Breliere JC, LeFur G, Nisto D, Pharmacological characterization of SR47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 265(2), 1993, 826-834.ISSN 1521-0103
3. 3. United States Pharmacopoeial Convention Inc. Rockville, 2011.
4. 4. Rahman N, Siddiqui MR, Azmi SN. Quantitative analysis of irbesartan in commercial dosage forms by kinetic spectrophotometry. Chem Pharm Bull (Tokyo). 2006 May;54(5):626-31. doi: 10.1248/cpb.54.626. PMID: 16651756.
5. 5. Ashour S, Bayram R, Selective and validated kinetic spectrophotometric method for the determination of irbesartan in pure and pharmaceutical formulations, Annales Pharmaceutiques Françaises, 77(2), 2019, 101-111. https://doi.org/10.1016/j.pharma.2018.09.002